Studying chronic skin diseases over time
Part of Skin clinical trials.
This study follows patients with common chronic skin conditions to see how they change over time. It does not test a new treatment, but collects data from regular doctor visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old.
- You have been diagnosed with atopic dermatitis, prurigo nodularis, psoriasis, chronic hand eczema, or hidradenitis suppurativa.
- You are a patient at the Fondazione Policlinico Universitario A. Gemelli IRCCS dermatology clinic.
- Your doctor has recorded your treatment start date and you have had at least one follow-up visit.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
This study looks at how people with certain immune-related skin diseases are treated in Italy. It will help doctors understand which treatments are used and why.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
Hear when a new Inflammatory Skin Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.